Biotia company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$2.4M | 2 yrs ago

About Biotia

Biotia provides hospital-acquired infection prevention powered by artificial intelligence and harnesses next-generation DNA sequencing to look at high-risk patients and prevent them from getting sick.

Biotia Headquarter Location

100 Avenue of the Americas 16th Floor

New York, New York, 10013,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biotia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biotia is included in 5 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

8,717 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

8,301 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

12,808 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,900 items

Latest Biotia News

First Hybridization Capture-Based NGS Covid-19 Assay Gets FDA EUA

Apr 2, 2021

First Hybridization Capture-Based NGS Covid-19 Assay Gets FDA EUA Twist Bioscience, South San Francisco, Calif, and Biotia, New York, NY, received emergency use authorization (EUA) from the FDA for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. The SARS-CoV-2 NGS Assay is an in vitro diagnostic test, a highly sensitive nucleic acid hybridization capture-based assay, intended for the detection of SARS-CoV-2 RNA. The SARS-CoV-2 NGS Assay has the ability to analyze the entire RNA viral sequence, to determine the presence or absence of the virus. Furthermore, in an optional research-use-only (RUO) report the software analyzes the RNA sequence to detect genetic variants and lineages of SARS-CoV-2. The hybridization capture-based approach utilized in this assay maximizes the number of genetic variants identified, where other sequencing methods may miss mutations in certain regions. New mutations in the SARS-CoV-2 virus continue to accumulate and circulate around the world, creating genetic variants of concern that may alter transmissibility or vaccine efficacy, including the most recent B.1.1.7, B.1.351, and P.1 lineages initially found in the UK, South Africa, and Brazil, respectively. Especially given these emerging variants, this capture-based method is an important new tool for the identification, sequencing, and surveillance of covid-19. According to the World Health Organization’s Genome Sequencing for SARS-CoV-2, published January 8, 2021, “One advantage of using a capture-based approach over a PCR amplicon-based approach is that capture-based approaches can tolerate sequence differences from the probe sequences of 10% to 20%. This is higher than the mismatch tolerated by PCR, where such a divergence from the primer sequences would result in a high risk of amplicon failure. Capture-based approaches can therefore be used to enrich successfully for relatively divergent SARS-CoV-2 sequences.” “While there are many available high-throughput diagnostic tests available for covid-19, our solution enables clinicians and researchers the ability to sequence and surveil the evolution of mutations in the virus over time and geography. This is especially significant at the moment as more variants are identified that are more contagious,” says Emily M. Leproust, PhD, CEO and co-founder of Twist Bioscience. “Importantly, while many labs are conducting individual sequencing runs for each patient sample, this assay and the accompanying software provide a way to batch about 100 samples together, providing actionable information that can then be used to inform public health and clinical decisions.” The assay utilizes Twist Bioscience’s unique ability to rapidly develop virus-specific panels through DNA synthesis and Biotia’s comprehensive data analysis software and reporting capabilities. The SARS-CoV-2 NGS Assay was validated on a NextSeq 550 Sequencing System. Because the assay analyzes the full sequence data, the test reduces the likelihood of a false-negative result. In contrast, a majority of SARS-CoV-2 tests based on polymerase chain reaction (PCR) only identify limited genetic markers of the virus. In the separate and free RUO report, the full sequence of the virus is profiled, enabling improved understanding of mutations, genetic variability, and the evolution of the virus as it’s transmitted. A recent  pre-print  on MedRxiv and submitted for peer review details results of the NGS SARS-CoV-2 Assay with the COVID-DX Solution to detect the virus and its genetic variants. “As SARS-CoV-2 continues to evolve, the need for insightful research tools leveraging NGS and evolutionary principles has become starkly clear,” commented Niamh O’Hara, PhD, CEO and co-founder of Biotia. “This assay also greatly expands testing options in the clinical space, bringing new technology to patients.” “This test opens the door to a new diagnostic method and can also guide vaccine research, since it captures viral variants so well,” says Christopher Mason, PhD, co-founder of Biotia. “We are elated to get an FDA EUA for our test, which brings needed tools into the fight against covid-19, as well as pioneering these capture methods for tracking other pathogens in the future.” Share:

Biotia Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biotia Rank

  • When was Biotia founded?

    Biotia was founded in 2016.

  • Where is Biotia's headquarters?

    Biotia's headquarters is located at 100 Avenue of the Americas, New York.

  • What is Biotia's latest funding round?

    Biotia's latest funding round is Seed VC.

  • How much did Biotia raise?

    Biotia raised a total of $2.4M.

  • Who are the investors of Biotia?

    Investors of Biotia include Hyperplane Venture Capital, The Fund, Falcon III Ventures and Digital Health Breakthrough Network.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.